• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Alteplase Increases Frequency of Functional Independence After Posterior Circulation Stroke

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 4, 2025.

FRIDAY, April 4, 2025 -- For patients with mainly mild posterior circulation ischemic stroke who do not receive thrombectomy, alteplase administered at 4.5 to 24 hours after onset results in higher frequency of functional independence at 90 days compared with standard medical care, according to a study published in the April 3 issue of the New England Journal of Medicine.

Shenqiang Yan, M.D., from the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and colleagues randomly assigned patients with posterior circulation ischemic stroke, without extensive early hypodensity on computed tomography and with no planned thrombectomy, to alteplase (0.9 mg/kg body weight; maximum dose, 90 mg) or standard medical treatment 4.5 to 24 hours after symptom onset (117 patients in each group). The primary outcome was functional independence (defined as a score of 0 to 2 on the modified Rankin scale; scores range from 0 to 6, with higher scores indicating greater disability) at 90 days.

The researchers found that the percentage of patients with functional independence at 90 days was higher in the alteplase group versus the standard treatment group (89.6 versus 72.6 percent; adjusted risk ratio, 1.16). The incidence of symptomatic intracranial hemorrhage within 36 hours was 1.7 and 0.9 percent in the alteplase and standard treatment groups, respectively. At 90 days, 5.2 and 8.5 percent of patients in the alteplase and standard treatment groups, respectively, had died.

"These results support the use of alteplase in this extended time window if endovascular thrombectomy is not available," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted April 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.